Therapeutic potential of micronized purified flavonoid fraction (MPFF) of diosmin and hesperidin in treatment chronic venous disorder

1. Beebe-Dimmer JL, Pfeifer J, Engel JS et al. The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 2005; 15(3): 175–184.

2. Vojtíšková J. Czech Vein Program – výsledky epidemiologického programu. Praktická flebologie 2012; 21: 8–13.

3. Eklöf B, Rutherford RR, Bergan JJ. Revision of the CEAP classification for chronic venous disorders: Consensus statement. J Vasc Surg.2004; 40(6): 1248–1252.

4. Bauer G. The etiology of leg ulcer and their treatment by resection of the popliteal vein. J Int Chir 1948; 8: 937–967.

5. Weindorf N, Schultz-Ehrenburg U. The development of varicose veins in children and adolescents (in German). Phlebologie 1990; 43(4): 573–577.

6. Markel A, Manzo RA, Bergelin RO et al. Valvular reflux after deep vein thrombosis: Incidence and time of occurence. J Vasc Surg 1992; 15(2): 377–382.

7. Danielsson G, Arfvidsson B, Ëklof B et al. Reflux from thigh to calf, the major pathology in chronic venous ulcer disease: surgery indicated in the majority of patients. Vasc Endovascular Surg 2004; 38(3): 209–219.

8. Dwerryhouse S, Davies B, Harradine K et al. Stripping of the long saphenous vein reduces the rate of reoperation for recurrent varicose veins: five years results of a randomized trial. J Vasc Surg 1999; 29(4): 589–592.

9. Jones L, Braithwaite BD, Selwyn D et al. Neovascularization is the principal cause of varicose vein recurrence: results of a randomized trial of stripping the long saphenous vein. Eur J Vasc Endovasc Surg 1996; 12(4): 442–445.

10. Gloviczki P, Bergan JJ, Rhodes JM et al. Mid-term results of endoscopic perforator vein interruption for chronic venous insufficiency: lessons learned from the North American subfascial endoscopic perforator surgery registry. The North American Study Group. J Vasc Surg 1999; 29(3): 489–502.

11. Gloviczki P. Development and anatomy of the venous system. In: Gloviczki P (ed). Handbook of venous Disorders. Guidelines of the American Venous Forum. 3rd ed. Hodder Arnold: London 2009. ISBN 978–03–409388–05.

12. Hnátek L. Farmakoterapie chronického žilního onemocnění. Interní medicína pro praxi 2014; 16(3): 93–97.

13. Ramelet AA, Boisseaub MR, Allegra C et al. Veno-active drugs in the management of chronic venous disease. An international consensus statement: Current medical position, prospective views and final resolution. Clin Hemorheol Microcirc 2005; 33(4): 309–319.

14. Godeberge P. Daflon 500 mg in the treatment of hemorrhoidal disease: a demostrated efficacy in comparison with placebo. Angiology 1994; 45(6 Pt 2): 574–578.

15. Misra MC, Parshad R. Randomised clinical trial of micronized flavonoids in the early control of bleeding from acute internal haemo­rrhoids. Br J Surg 2000; 87(7): 868–872.

16. Cospite M. Double-blind, placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemoroids. Drugs Today 1995; 31(Suppl E): 49–55.

17. Ho YH, Foo CL, Seow-Choen F et al. Prospective randomized controlled trial of micronized flavonoidic fraction to reduce bleeding after haemorrhoidectomy. Br J Surg 1995; 82(8): 1034–1035.

18. Cotonat A, Cotonat J. Lymphagogue and pulsatile activities of Daflon 500 mg on canine thoracic lymph duct. Int Angiol 1989; 8(Suppl 4): S15-S18.

19. Allegra C, Bartolo MJr, Carioti B et al. Microlymphography: assessment of Daflon 500 mg activity in patients with chronic venous insufficiency. Lymphology 1997; 31(Suppl): 12–16.

20. Pecking AP, Février B, Wargon C et al. Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer). Angiology 1997; 48(1): 93–98.

21. Gelle P, Crepin G, Delahousse G. Varices in pregnancy. Use of Daflon. Lille Med 1972; 17(Suppl 7): 1466–1468.

22. Navrátilová Z. Efficacy of a 6-month treatment with Detralex in Patients with venous edema. Phlebolymphology 2010; 17(3): 137–143.

23. Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol 2012; 31(4): 310–315.

24. Lenkovic M, Zgombic ZS, Blazic TM et al. Benefit of Daflon 500 mg in the reduction of chronic venous disease-related symptoms. Phlebolymphology 2012; 19(2): 79–83.

25. Danzinger N. Patophysiology of pain in venous disease. J Mal Vasc 2007; 32(1):1–7.

26. Takase S, Pascarella L, Lerond Let al. Venous hypertension, inflammation and valve remodeling. Eur J Vasc Endovasc Surg 2004; 28(5): 484–493.

27. Pascarella L, Lulic D, Penn AH et al. Mechanisms in experimental venous valve failure and their modification by Daflon 500 mg. Eur J Vasc Endovasc Surg 2008; 35(1):102–110.

28. Iriz E, Vural C, Ereren E et al. Effects of calcium dobesilate and diosmin-hesperidin on apoptosis of venous wall in primary varicose veins. Vasa 2008; 37(3): 233–240.

29. Nicolaides AN. From symptomps to leg edema:efficacy of Daflon 500 mg. Angiology 2003; 54(Suppl 1): S33-S44.

30. Shoab SS, Porter JB, Scurr JH et al. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000; 31(3): 456–461.

31. Korthuis RJ, Gute DC. Adhesion molecule expression in postischemic microvascular dysfunction: activity of a micronized purified flavonoid fraction. J Vasc Res 1999; 36(Suppl 1): S15-S23.

32. Tsoukanov YT, Tsoukanov AY, Nikolaychuk A. Great saphenous vein transitory reflux in patients with symptoms related to chronic venous disorders, but without visible signs (C0s), and its correction with MPFF treatment. Phlebolymphology 2015; 22(1): 25.

33. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a meta-analysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005; 30(2): 198–208.

34. Roztočil K, Štvrtinová V, Strejček J. Efficacy of 6-month treatment with Daflon 500 mg in patients with venous leg ulcers associated with chronic venous insufficiency. Int Angiol 2003; 22(1): 24–31.

35. Pokrovsky AV, Saveljev VS, Kirienko AI et al. Stripping of the great saphenous vein under micronized purified flavonoid fraction (MPFF) protection (results of the Russian multicenter controlled trial DEFANCE). Phlebolymphology 2008; 15(2): 45–51.

36. Veverkova L, Jedlicka V, Wechsler J et al. Analysis of the various procedures used in great saphenous vein surgery in the Czech Republic and benefit of Daflon 500 mg to postoperative symptoms. Phlebolymphology 2006; 13(4): 181–220.

37. Pitsch F. Benefit of Daflon 500 mg in combination with sclerotherapy of teleangiectasias of the lower limbs: results form the SYNERGY and SATISFY surveys. Phlebolymphology 2011; 19(4): 182–187.

38. Bogachev VY, Golovanova OV, Kuznetsov AN et al. Can Micronized Purified Flavonoid Fraction (MPFF) improve outcomes of lower extremity varicose vein endovenous treatment? First results from DECISION study. Phlebolypmphology 2013; 20(4): 181–187.

39. Crébassa V, Karihuel J. Micronized Purified Flavonoid Fraction Treatment Improves Cutaneous Outcomes and Patient’s Satisfaction with Sclerotherapy for Superficial Varicosities. Int Angiol 2013; 32(5 Suppl 1): 105.

40. Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg 2011; 41(1): 117–125.

41. Perrin M, Nicolaides A. The Updates International Guidelines on The Management of Chronic Venous Disorders of the Lower Limbs and the Place of Venoactive Drugs. Int Angiol 2013; 32(5 Suppl 1): 106–107.

42. Nicolaides AN, Kakkos S. Management of chronic venous disorders of the lower limbs. Guidelines according to scientific evidence. Int Angiol 2014; 33(2): 87–208.

43. The Essentials from the XVIIth World Meeting of the Union Internationale de Phlébologie, 7–14 September 2013, Boston, USA. Phlebolymphology 2013; 20(3): 138–144.

44. Perrin M. Efficacy of vasoactive drugs in primary chronic venous disease survey of evidence, synthesis, and recommendations. In: Bergan JJ, Bunke N (eds) et al. The Vein Book. 2nd ed. Oxford University Press 2014: 514–527. ISBN 978–0-19–539963–9.